Article successfully added.

CyFlow™ CD18 FITC

CyFlow™ CD18 FITC
Alternative Name: b2 integrin
Antigen: CD18
Application: Flow cytometry
Clonality: monoclonal
Clone: M18/2
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Field of Interest: Immunophenotyping, MHC
Format/Fluorochrome: FITC
Isotype: IgG2a
Laser: Blue
Regulatory Status: RUO
Source Species: Rat
Target Species: Mouse
Product number: AQ070678

For Research Use Only

$276.71 CAD*

Price excludes any applicable taxes plus shipping costs

Build Your Own Reagent Panel
Concentration Unit mg/mL Concentration 0,5 Quantity 0.1 mg Volume 0.2 mL... more
CyFlow™ CD18 FITC
Concentration Unitmg/mL
Concentration0,5
Quantity0.1 mg
Volume0.2 mL
ImmunogenMouse cytotoxic T cell glycoproteins
Background InformationCD18 (integrin β2 subunit) forms heterodimers with four types of CD11 molecule to constitute leukocyte (β2) integrins: αLβ2 (CD11a/CD18, LFA-1), αMβ2 (CD11b/CD18, Mac-1, CR3), αXβ2 (CD11c/CD18) and αDβ2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits. These integrins are essential for proper leukocyte migration, mediating intercellular contacts.
UsageThe reagent is designed for Flow Cytometry analysis. Suggested working usage is 3·µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Sanchez-Madrid F, Simon P, Thompson S, Springer TA: Mapping of antigenic and functional epitopes on the alpha‑ and beta‑subunits of two related mouse glycoproteins involved in cell interactions, LFA‑1 and Mac‑1. J Exp Med. 1983 Aug 1; 158(2):586‑602. < PMID: 6193226 > | Zahalka MA, Okon E, Naor D: Blocking lymphoma invasiveness with a monoclonal antibody directed against the beta‑chain of the leukocyte adhesion molecule (CD18). J Immunol. 1993 May 15; 150(10):4466‑77. < PMID: 8097756 > | Zahalka MA, Naor D: Beta 2‑integrin dependent aggregate formation between LB T cell lymphoma and spleen cells: assessment of correlation with spleen invasiveness. Int Immunol. 1994 Jun; 6(6):917‑24. < PMID: 7522049 > | Avni O, Pur Z, Yefenof E, Baniyash M: Complement receptor 3 of macrophages is associated with galectin‑1‑like protein. J Immunol. 1998 Jun 15; 160(12):6151‑8. < PMID: 9637533 > | Abraham C, Miller J: Molecular mechanisms of IL‑2 gene regulation following costimulation through LFA‑1. J Immunol. 2001 Nov 1; 167(9):5193‑201. < PMID: 11673532 > | Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, Adamis AP, Ambati J: Targeted disruption of the CD18 or ICAM‑1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003 Jun; 44(6):2743‑9. < PMID: 12766082 > | Barlow SC, Langston W, Matthews KM, Chidlow JH Jr, Kevil CG: CD18 deficiency protects against multiple low‑dose streptozotocin‑induced diabetes. Am J Pathol. 2004 Dec; 165(6):1849‑52. < PMID: 15579429 > | Watts GM, Beurskens FJ, Martin-Padura I, Ballantyne CM, Klickstein LB, Brenner MB, Lee DM: Manifestations of inflammatory arthritis are critically dependent on LFA‑1. J Immunol. 2005 Mar 15; 174(6):3668‑75. < PMID: 15749905 > | Varga G, Balkow S, Wild MK, Stadtbaeumer A, Krummen M, Rothoeft T, Higuchi T, Beissert S, Wethmar K, Scharffetter-Kochanek K, Vestweber D, Grabbe S: Active MAC‑1 (CD11b/CD18) on DCs inhibits full T‑cell activation. Blood. 2007 Jan 15; 109(2):661‑9. < PMID: 17003381 > | Cullere X, Lauterbach M, Tsuboi N, Mayadas TN: Neutrophil‑selective CD18 silencing using RNA interference in vivo. Blood. 2008 Apr 1; 111(7):3591‑8. < PMID: 18216298 >